
QIAGEN Fourth Quarter and Year End 2002 Conference Call February 19, 2003

Dr. Metin Colpan, Managing Director and CEO Peer M. Schatz, Managing Director and CFO

Dr. Solveigh Mähler, Manager Investor Relations



Welcome to QIAGEN's Fourth Quarter and Year End 2002 Conference Call





Forward Looking Statements


Certain of the statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products and markets and operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the DNA sequencing, genomics and synthetic nucleic acid-related markets, as well as the nucleic acid-based molecular diagnostics and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's products (including seasonal fluctuations), difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors, and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that QIAGEN has filed with the U.S. Securities and Exchange Commission (SEC).




Note: The following slides contain certain summary information about QIAGEN N.V.'s operating income, net income, and earnings per share for the fourth quarter and fiscal 2002, and the comparable periods of 2001, which information is presented on a "pro forma" basis rather than in accordance with U.S. generally accepted accounting priniciples ("GAAP"). Please review QIAGEN's press release dated February 18, 2003, for information on the company's operating income, net income, and earnings per share for these periods presented on a GAAP basis. Such GAAP-basis information will also be contained in the company's report on Form 6-K to be filed with the U.S. Securities and Exchange Commission.



QIAGEN's product breakdown - worldwide




QIAGEN Consumable Business: Continuous Strong Growth



QIAGEN


Genesilencing and RNA Expressionprofiling



Xeragon RNAi Customized RNAi RNAi Sets Cancer Sets RNeasy Kits Fibrous Tissue Lipid Tissue Blood Quantitect Probes Quantitect Assays HotStart Taq



Epoch Genexpression Probes



Qamp Dneasy Flexigene MagAttract

QuantiTec



QIAGEN's Instrumentation Business

QIAGEN BioRobots differ from other instrumentation businesses due to:

- Other than a generic instrument, a BioRobot is a closed, solution-specific instrument
- QIAGEN BioRobots are very focused on specific applications: separation, purification and handling nucleic acids
- QIAGEN BioRobots and QIAGEN consumables are an inseparable unit
- QIAGEN BioRobots are essential for QIAGEN's strategy and allow QIAGEN to address some of the most exciting markets
- QIAGEN BioRobots show exciting growth rate with 34% Q4 over Q3




The BioRobot Product Line



Consumables







QIAGEN

Slide 11

Eays 1 Integrated Preanalytical Solution



BioRobot MDx








QIAGEN

Research Budget per Customer Segment




Slide 14

Money flows ...

Academic Markets (>50% of QIAGEN's customer base)

- QIAGEN further increased market and technology leadership
- shift from sequencing to functional genomics and proteomics
- increased variety of samples and more complex and sensitive detection and analysis technologies demand highly reproducible and integrated purification solutions







NIH Budget

Risk is NOT a changing growth rate

- NIH focus on specific R&D areas which turn into QIAGEN's direction
 - systems biology
 - quantitative analysis of dynamic genome-wide expression patterns
 - analysis of complex molecular networks and their regulations
 - development of advanced research technologies
 - molecular libraries such as an RNAi library
 - understanding of specific diseases like Alzheimer, infectious diseases at the level of genes, proteins and dynamic systems and
 - improve the national clinical research infrastructure (eradication of inefficciencies in clinical trials system)

Risk is the NIH Grants Policy in times BEFORE offical approval

- most grants currently being awarded as "Noncompeting Continuation Awards"
 - project specific period system of funding
 - only 70% of prior year budget available in cases of budget delays



Trends to watch in U.S. Research Grants

NIH Budget focussing on specific disease areas


- Cancer Research
- AIDS vaccines
- Infectious Diseases
- Vaccine development
- Women's Health
- Diabetes
- Anthrax Research
- Increased military spending
- DARPA grants
- Focussing on Biowarfare

Bioterrorism

- Large budget increase for homeland security
- Public health infrastructure, research




NIH Budget Allocation – Shift in LifeScience Research by Focussing on Specific Areas



QIAGEN

Money flows ...

Customers in Big Pharma (35% of QIAGEN's customer base)






- QIAGEN further increased market and technology leadership
- Analysts' estimates on 2003 R&D budget growth: 8%
- shift from sequencing to functional genomics and proteomics
- increased variety of samples and more complex and sensitive detection and analysis technologies demand highly reproducible and integrated purification solutions



Money flows ...

Biotech Markets (15% of QIAGEN's customer base)




Top 10 Biotechnology Companies represent approximately 45% of total Biotech R&D Budget

- 2003 estimated R&D budget growth of the Top 20 Biotech Companies: 16%
- shift from sequencing to functional genomics and proteomics
- increased variety of samples and more complex and sensitive detection and analysis technologies demand highly reproducible and integrated purification solutions




Geographic distribution of revenue growth 2001 to 2002





Geographic distribution of net sales



QIAGEN 2002

Revenues:	2002:	\$ 298.6 million	96–02 CAGR:	33%
Net income:	2002:	\$ 33.3* million	96–02 CAGR:	36%*
EPS:	2002:	\$ 0.23 *	96-02 CAGR:	34%*

Product range:

- Approx. 320 consumable products
- Instrumentation
- Increased range of in-licensed technologies

IP:

- 246 issued patents, 201 pending patents
- Over 400 patents under license

Customers:

400,000 scientists worldwide

* excluding one-time charges related to the acquisition of GenoVision A.S. as well as restructuring charges related to the closing of QIAGEN Genomics, Inc.)
Innovation Working for You



QIAGEN Fourth Quarter 2002

	Q4 2002	Q4 2001	Growth
Revenues (\$ million)	78.4	71.2	10%
EBIT margin (%)	20.0*	24.0	
Operating Income (\$ million)	5.2	17.1	-70%
adjusted	15.9*	15.1**	6%
Net Income (\$ million)	1.8	10.9	-84%
adjusted	9.7*	9.8**	unchanged*
EPS	\$ 0.01/0.07*	\$ 0.08/0.07**	unchanged*
WA Number of Shares	146.1	145.1	

* excluding charges related to the closing of QIAGEN Genomics, Inc.

** excluding charges related to the acquisition of Sawady Group of companies



QIAGEN Fourth Quarter 2002

	Operating Income				
	2002 QTD	2001 QTD			
Reported US GAAP Closure and related costs Acquisition and related costs	\$ 5.176.000 10.773.000	\$ 17.127.000			
Gain related to Sawady		(2.031.960)			
Adjusted	\$ 15.949.000	\$ 15.095.040			
	Net Income				
	2002 QTD	2001 QTD			
Reported US GAAP Closure and related costs	\$ 1.773.000 7.973.000	\$ 10.934.000			
Acquisition and related costs Net gain related to Sawady Gain on sale of financial asset		(1.178.537)			
Adjusted	\$ 9.746.000	\$ 9.755.463			
tion Working for You					



Slide 25

QIAGEN Full Year 2002

	2002	2001	Growth
Revenues (\$ million)	298.6	263.8	13%
Operating Income (\$ million)	43.2	53.5	-19%
adjusted	56.8*	54.4 [†]	4%
Net Income (\$ million)	23.1	34.4	-33%
adjusted	33.3*	33.9 ^{††}	-2%*
EPS	\$ 0.16 / 0.23*	\$ 0.24 / 0.23 ^{††}	unchanged*
WA Number of Shares	145.9	145.1	
Employees (approx.) Cash, Marketable Securities	1,651	1,557	6%
(\$ million)	56.4	79.0	

 excluding one-time charges related to the acquisitions of GenoVision AS as well as a charge related to the closing of QIAGEN Genomics, Inc.

[†] one-time charges related to the acquisition of the Sawady Group and

tt excluding a gain on the sale of a financial asset




QIAGEN Full Year 2002

	Operating Income				
	2002 YTD	2001 YTD			
Reported US GAAP Closure and related costs	\$ 43.185.000 10.773.000	\$ 53.476.000			
Acquisition and related costs	2.848.000	3.000.000			
Gain related to Sawady		(2.031.960)			
Adjusted	\$ 56.806.000	\$ 54.444.040			
	Net In	icome			
	2002 YTD	2001 YTD			
Reported US GAAP	\$ 23.142.000	\$ 34.419.000			
Closure and related costs	7.973.000				
Acquisition and related costs	2.215.000	2.035.815			
Net gain related to Sawady		(1.178.537)			
Gain on sale of financial asset		(1.372.830)			
		¢ 22 002 440			
Adjusted	\$ 33.330.000	\$ 33.903.448			



Slide 27

Currency Effects on Revenues and Expenses



QIAGEN

Employees December 31, 2002

	US/ Can	Ger	UK	F	Nor	СН	Aus	JP	NL	Italy	Total 2002	Total 2001	Growth
Production	143	305			1	49		28			526	410	28%
R&D	21	219			10	29					279	328	-15%
Sales	211	134	37	23	3	18	12	39		7	484	444	9%
Marketing	57	48	4	1	2	4		6		1	123	138	-11%
Admin	92	105	4	5	1	12	4	9	4	3	239	237	1%
Total	524	811	45	29	17	112	16	82	4	11	1651	1557	6%



Pharma markets are weak?

Second only to the molecular diagnostics market, pharma represented QIAGEN's <u>fastest growing segment</u>

Capital expenditures are down?


QIAGEN's instrumentation solutions showed 35% growth vs. Q3.

Currency was the big effect?

Currency had approx. \$600,000 impact vs. time at which we gave guidance for Q4.




QIAGEN Guidance on 2003





QIAGEN Consumable Business: Continuous Strong Growth




IAGEN

Forward Looking Statements

2001


2002



in % Total Sales

in % Total Sales

QIAGEN



Slide 33

- New production and R&D site in Germantown, MD, U.S. (01/02)
- New production and office site in Hilden, Germany (10/02)
- Acquisition of Xeragon, Inc. (03/02)
- Acquisition of GenoVision A.S. (05/02)



QIAGEN partnered

- QIAGEN and Roche Diagnostics partner in developing an integrated Diagnostic System für HEP and HIV PCR Testing
- PreAnalytiX Supply Agreement with GlaxoSmithKline
- Supply Agreement expansion with Affymetrix
- Alliance with Leica Microsystems targeting Laser Microdissection (LMD) Applications
- Global Marketing Agreement with EPOCH Biosciences, Inc. for MGB EclipseTM Probe Systems for RT gene expression analysis
- Cooperation with Axxima on protein kinases and phosphatases analysis on SensiChip Platform



QIAGEN launched

- Launch of the
 - new exciting clinical BioRobot MDx generation
 - BioRobot M product line
 - EZ 1 BioRobot Generation
 - BioRobot HT Plasmid System
 - SensiChip platform
 - LiquiChip platform
 - first siRNA cancer oligo Set



QIAGEN increased efficiencies

- lowered cost base by closing Seattle facility and leveraging U.S. presences Maryland and California
- initiated cost reduction program in synthetic DNA business



QIAGEN Financial Calendar 2003

June 11, 2003

Annual General Meeting, Venlo

August 04, 2003

October 27, 2003

Q2, First Half 2003

Q3 2003

